{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Test+formulation+%28Treatment+C%29&page=2", "query": { "intervention": "Test formulation (Treatment C)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Test+formulation+%28Treatment+C%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-27T05:42:26.983Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03311373", "title": "A Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of PT010", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "Regimen A", "type": "DRUG" }, { "name": "Regimen B", "type": "DRUG" }, { "name": "Regimen C", "type": "DRUG" }, { "name": "Regimen D", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pearl Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 56, "start_date": "2017-10-17", "completion_date": "2017-12-15", "has_results": true, "last_update_posted_date": "2020-06-11", "last_synced_at": "2026-09-27T05:42:26.983Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03311373" }, { "nct_id": "NCT04553042", "title": "A Study of Seltorexant in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Seltorexant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 69, "start_date": "2020-09-14", "completion_date": "2020-12-30", "has_results": false, "last_update_posted_date": "2025-04-27", "last_synced_at": "2026-09-27T05:42:26.983Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04553042" }, { "nct_id": "NCT02083640", "title": "Relative Bioavailability For Palbociclib Formulations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Palbociclib Formulation Reference", "type": "DRUG" }, { "name": "Palbociclib Formulation Test", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 30, "start_date": "2014-03", "completion_date": "2014-05", "has_results": false, "last_update_posted_date": "2014-06-04", "last_synced_at": "2026-09-27T05:42:26.983Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02083640" }, { "nct_id": "NCT02031666", "title": "A Study to Assess the Relative Bioavailability of 7 Test Tablet Formulations of JNJ-56021927 With Respect to the Capsule Formulation of JNJ-56021927 in Healthy Male Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "JNJ-56021927 capsule", "type": "DRUG" }, { "name": "JNJ-56021927 tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aragon Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "MALE", "summary": "18 Years to 55 Years · Male only" }, "enrollment_count": 120, "start_date": "2013-12", "completion_date": "2014-04", "has_results": false, "last_update_posted_date": "2016-10-20", "last_synced_at": "2026-09-27T05:42:26.983Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02031666" }, { "nct_id": "NCT05236231", "title": "A Study of Fixed Dose Combination of Macitentan/Tadalafil (10 mg/20 mg) Compared to the Reference Free Combination of Macitentan and Tadalafil in Healthy Adult Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Macitentan 10 mg", "type": "DRUG" }, { "name": "Tadalafil 20 mg", "type": "DRUG" }, { "name": "Macitentan 10 mg/Tadalafil 20mg FDC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Actelion", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 40, "start_date": "2022-02-04", "completion_date": "2022-05-14", "has_results": false, "last_update_posted_date": "2025-03-30", "last_synced_at": "2026-09-27T05:42:26.983Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05236231" }, { "nct_id": "NCT03137134", "title": "A Study to Evaluate the Effects of Food and Esomeprazole on the Pharmacokinetics of Crizotinib in a Coated Microsphere Formulation.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Crizotinib", "type": "DRUG" }, { "name": "Esomeprazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 18, "start_date": "2017-06-20", "completion_date": "2017-10-17", "has_results": false, "last_update_posted_date": "2017-10-31", "last_synced_at": "2026-09-27T05:42:26.983Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03137134" }, { "nct_id": "NCT07723833", "title": "A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "Elecoglipron Reference Formulation Dose A", "type": "DRUG" }, { "name": "Elecoglipron Test formulation 1 Dose A", "type": "DRUG" }, { "name": "Elecoglipron Reference Formulation Dose B", "type": "DRUG" }, { "name": "Elecoglipron Test formulation 1 Dose B", "type": "DRUG" }, { "name": "Elecoglipron Test formulation 2 Dose A", "type": "DRUG" }, { "name": "Elecoglipron Test formulation 2 Dose B", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 152, "start_date": "2026-07-27", "completion_date": "2026-11-18", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-09-27T05:42:26.983Z", "location_count": 2, "location_summary": "Glendale, California • Brooklyn, Maryland", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Brooklyn", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07723833" }, { "nct_id": "NCT01142063", "title": "A Single Dose Bioequivalence Study Of Neratinib In Healthy Subjects", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Healthy" ], "interventions": [ { "name": "Neratinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Puma Biotechnology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 28, "start_date": "2010-06", "completion_date": "2010-09", "has_results": false, "last_update_posted_date": "2012-05-14", "last_synced_at": "2026-09-27T05:42:26.983Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01142063" }, { "nct_id": "NCT02248779", "title": "Assessing Insulin Sensitivity and Diabetes Risk in Childhood Cancer Survivors Treated With Abdominal Irradiation", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Childhood Cancer Survivors Treated With Abdominal Radiation" ], "interventions": [], "intervention_types": [], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 42, "start_date": "2014-09-22", "completion_date": "2019-10-09", "has_results": false, "last_update_posted_date": "2019-10-15", "last_synced_at": "2026-09-27T05:42:26.983Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02248779" }, { "nct_id": "NCT03682380", "title": "A Study of Seltorexant (JNJ-42847922) After Single-Dose Administration in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Seltorexant High Dose", "type": "DRUG" }, { "name": "Seltorexant Low Dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 151, "start_date": "2018-10-01", "completion_date": "2019-08-23", "has_results": false, "last_update_posted_date": "2025-04-27", "last_synced_at": "2026-09-27T05:42:26.983Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT03682380" } ] }